Research programme: cannabinoid-2 receptor agonists - Schering-PloughAlternative Names: Cannabinoid-2 receptor agonists - Schering-Plough; CB2 receptor agonists - Schering-Plough; SCH-336; Sch.336
Latest Information Update: 17 Nov 2009
At a glance
- Originator Schering-Plough
- Mechanism of Action Cannabinoid receptor CB2 agonists; Immunosuppressants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Asthma
Most Recent Events
- 27 Jun 2006 Preclinical trials in Asthma in USA (PO)